Who is sponsoring NCT05466591?

NCT05466591 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT05466591?

Interventions in NCT05466591: Pre-hospital rule-out strategy.

What condition does NCT05466591 study?

NCT05466591 studies Acute Coronary Syndrome.

Is NCT05466591 still recruiting?

NCT05466591 is currently status unknown. Last updated 25 July 2022.

Last reviewed 2022-07-25 · How we verify

NCT05466591: ARTICA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pre-hospital Rule-out of Acute Coronary Syndrome

Status unknown NA Last updated 25 July 2022

What this trial tests

NA trial testing Pre-hospital rule-out strategy in Acute Coronary Syndrome in 866 participants. Status unknown.

Timeline

1 March 2019

Primary endpoint
4 June 2022

4 May 2023

Quick facts

Lead sponsor	Radboud University Medical Center
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	diagnostic
Enrollment	866
Start date	1 March 2019
Primary completion	4 June 2022
Estimated completion	4 May 2023
Sites	1 location across Netherlands

Drugs / interventions tested

Pre-hospital rule-out strategy

Conditions studied

Acute Coronary Syndrome — all drugs for Acute Coronary Syndrome →

Sponsor

Radboud University Medical Center

Who can join

18 and older, any sex, with Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with chest pain suspected for non ST-segment elevation acute coronary syndrome (NSTE-ACS) are routinely transferred to the emergency department (ED). A point-of-care (POC) troponin measurement might enable ambulance paramedics to identify low-risk patients in whom ED evaluation is not necessary. The ARTICA trial aims to assess the healthcare cost reduction and safety of a pre-hospital rule-out strategy using a single POC troponin measurement.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Rule-out of non-ST-segment elevation acute coronary syndrome by a single, pre-hospital troponin measurement: a randomized trial.
Camaro C, Aarts GWA, Adang EMM, van Hout R, et al · · 2023 · cited 41× · PMID 36755110 · DOI 10.1093/eurheartj/ehad056
Pre-hospital rule-out of non-ST-segment elevation acute coronary syndrome by a single troponin: final one-year outcomes of the ARTICA randomised trial.
Aarts GWA, Camaro C, Adang EMM, Rodwell L, et al · · 2024 · cited 9× · PMID 38236708 · DOI 10.1093/ehjqcco/qcae004
Differences in risk and costs between prehospital identified low-risk men and women with chest pain.
Aarts GWA, Camaro C, Rodwell L, Adang EMM, et al · · 2023 · cited 1× · PMID 38011992 · DOI 10.1136/openhrt-2023-002390
Pre-hospital rule-out of acute coronary syndrome by modified HEART score assessment including point-of-care troponin.
Camaro C, Aarts GWA, van Royen N, ARTICA investigators. · · 2022 · cited 1× · PMID 36260200 · DOI 10.1007/s12471-022-01726-3

Verify or expand the search:

Other recruiting trials for Acute Coronary Syndrome

Currently open trials in the same condition.

NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
NCT07032389 — A Polypill for Acute Coronary Syndrome · Phase 2 · recruiting
NCT07102628 — Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronar · Phase 3 · recruiting
NCT06416813 — Preventive Intervention Value of DCB in Vulnerable Coronary Atherosclerotic Plaques · NA · active not recruiting

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05466591 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 25 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05466591.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing